Cytek Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $201.5M | $200.5M | $193.0M | $164.0M | $128.0M |
| Gross profit | $104.5M | $111.1M | $109.4M | $101.0M | $79.1M |
| Operating income | -$40.4M | -$20.5M | -$27.8M | -$1.8M | $9.2M |
| Operating expenses | $144.8M | $131.6M | $137.3M | $102.8M | $70.0M |
| Cost of revenue | $97.0M | $89.3M | $83.6M | $63.1M | $48.8M |
| Cash from operations | -$4.7M | $25.4M | $5.3M | -$12.2M | $4.6M |
| Capital expenditure | $4.1M | $3.5M | $4.6M | $9.7M | $4.4M |
| Free cash flow | -$8.8M | $21.9M | $633,000 | -$22.0M | $266,000 |
| Share repurchases | $15.1M | $21.6M | $44.2M | $0 | $0 |
| Total assets | $461.5M | $499.5M | $494.5M | $519.5M | $463.3M |
| Total liabilities | $119.8M | $103.8M | $101.4M | $93.9M | $57.9M |
| Total debt | $525,000 | $1.1M | $1.6M | $2.3M | $0 |
Shares outstanding 129.1M · Free float 89.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.